Research ArticleOriginal Article

Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial

Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

References

  1. 1.↵
    2. Brackstone M,
    3. Baldassarre FG,
    4. Perera FE,
    5. Cil M,
    6. Gregor MCM,
    7. Dayes IS, et al.
    Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol. 2021; 39 27 3056–82.
    OpenUrl
  2. 2.
    2. Rao R,
    3. Euhus D,
    4. Mayo HG,
    5. Balch C .
    Axillary node interventions in breast cancer: a systematic review. JAMA. 2013; 310: 1385–94.
    OpenUrlPubMed
  3. 3.↵
    2. Veronesi U,
    3. Paganelli G,
    4. Viale G,
    5. Luini A,
    6. Zurrida S,
    7. Galimberti V, et al.
    A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349: 546–53.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    2. Gentilini O,
    3. Botteri E,
    4. Dadda P,
    5. Sangalli C,
    6. Boccardo C,
    7. Peradze N, et al.
    Physical function of the upper limb after breast cancer surgery. Results from the SOUND (Sentinel node vs. Observation after axillary Ultra-souND) trial. Eur J Surg Oncol. 2016; 42: 685–9.
    OpenUrl
  5. 5.↵
    2. Giuliano AE,
    3. Hunt KK,
    4. Ballman KV,
    5. Beitsch PD,
    6. Whitworth PW,
    7. Blumencranz PW, et al.
    Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011; 305: 569–75.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    2. Bromham N,
    3. Schmidt-Hansen M,
    4. Astin M,
    5. Hasler E,
    6. Reed MW .
    Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev. 2017; 1: CD004561.
  7. 7.↵
    2. Miller KD,
    3. Nogueira L,
    4. Mariotto AB,
    5. Rowland JH,
    6. Yabroff KR,
    7. Alfano CM, et al.
    Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69: 363–85.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Hwang S,
    3. Lee SW,
    4. Kim HJ,
    5. Kim WW,
    6. Park HY,
    7. Jung JH .
    The comparative study of ultrasonography, contrast-enhanced MRI, and (18)F-FDG PET/CT for detecting axillary lymph node metastasis in T1 breast cancer. J Breast Cancer. 2013; 16: 315–21.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Ueda S,
    3. Tsuda H,
    4. Asakawa H,
    5. Omata J,
    6. Fukatsu K,
    7. Kondo N, et al.
    Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer. 2008; 8: 165.
    OpenUrlCrossRefPubMed
  10. 10.↵
    2. Cheng J,
    3. Li J,
    4. Liu G,
    5. Shui R,
    6. Chen S,
    7. Yang B, et al.
    Diagnostic performance of a novel high-resolution dedicated axillary PET system in the assessment of regional nodal spread of disease in early breast cancer. Quant Imaging Med Surg. 2022; 12: 1109–20.
    OpenUrl
  11. 11.↵
    2. Giuliano AE,
    3. Ballman KV,
    4. McCall L,
    5. Beitsch PD,
    6. Brennan MB,
    7. Kelemen PR, et al.
    Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017; 318: 918–26.
    OpenUrlCrossRefPubMed
  12. 12.↵
    2. Galimberti V,
    3. Cole BF,
    4. Viale G,
    5. Veronesi P,
    6. Vicini E,
    7. Intra M, et al.
    Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19: 1385–93.
    OpenUrlPubMed
  13. 13.↵
    2. Donker M,
    3. van Tienhoven G,
    4. Straver ME,
    5. Meijnen P,
    6. van de Velde CJH,
    7. Mansel RE, et al.
    Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014; 15: 1303–10.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    2. van Roozendaal LM,
    3. Vane MLG,
    4. van Dalen T,
    5. van der Hage JA,
    6. Strobbe LJA,
    7. Boersma LJ, et al.
    Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08). BMC Cancer. 2017; 17: 459.
    OpenUrl
  15. 15.↵
    2. Nadeem RM .
    The feasibility of SNIPE trial; sentinel lymph node biopsy vs. no-SLNB in patients with early breast cancer. Cancer Res. 2013; 73(24 suppl): P1-01.
  16. 16.↵
    2. Schipper RJ,
    3. van Roozendaal LM,
    4. deVries B,
    5. Pijnappel RM,
    6. Beets-Tan RGH,
    7. Lobbes MBI, et al.
    Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value? Breast. 2013 1108–13.
  17. 17.↵
    2. Nwaogu IY,
    3. Yan Y,
    4. Appleton CM,
    5. Cyr AE,
    6. Margenthaler JA .
    Predictors of false negative axillary ultrasound in breast cancer. J Surg Res. 2015; 198: 351–4.
    OpenUrl
  18. 18.↵
    2. Tucker NS,
    3. Cyr AE,
    4. Ademuyiwa FO,
    5. Tabchy A,
    6. George K,
    7. Sharma PK, et al.
    Axillary ultrasound accurately excludes clinically significant lymph node disease in patients with early stage breast cancer. Ann Surg. 2016; 264: 1098–102.
    OpenUrl
  19. 19.↵
    2. Veronesi U,
    3. De Cicco C,
    4. Galimberti VE,
    5. Fernandez JR,
    6. Rotmensz N,
    7. Viale G, et al.
    A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2007; 18: 473–8.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    2. Kasem J,
    3. Wazir U,
    4. Mokbel K .
    Sensitivity, specificity and the diagnostic accuracy of PET/CT for axillary staging in patients with stage I-III cancer: a systematic review of the literature. In Vivo. 2021; 35: 23–30.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    2. Koolen BB,
    3. Aukema TS,
    4. Martínez AJG,
    5. Vogel WV,
    6. Ontanaya LC,
    7. Peeters MJV, et al.
    First clinical experience with a dedicated PET for hanging breast molecular imaging. Q J Nucl Med Mol Imaging. 2013; 57: 92–100.
    OpenUrl
  22. 22.↵
    2. Cheng J,
    3. Ren C,
    4. Liu G, et al.
    Development of high-resolution dedicated PET-based radiomics machine learning model to predict axillary lymph node status in early-stage breast cancer. Cancers. 2022; 14: 950.
    OpenUrl
  23. 23.↵
    2. Hansen NM,
    3. Grube B,
    4. Ye X,
    5. Turner RR,
    6. Brenner RJ,
    7. Sim MS, et al.
    Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol. 2009; 27: 4679–84.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    2. Montagna E,
    3. Viale G,
    4. Rotmensz N,
    5. Maisonneuve P,
    6. Galimberti V,
    7. Luini A, et al.
    Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breast Cancer Res Treat. 2009; 118: 385–94.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    2. Veronesi U,
    3. Orecchia R,
    4. Zurrida S,
    5. Galimberti V,
    6. Luini A,
    7. Veronesi P, et al.
    Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol. 2005; 16: 383–8.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    2. Gluz O,
    3. Nitz UA,
    4. Christgen M,
    5. Kates RE,
    6. Shak S,
    7. Clemens M, et al.
    West German Study Group Phase III PlanB Trial: First prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 2016; 34: 2341–9.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    2. Cardoso F,
    3. van’t Veer LJ,
    4. Bogaerts J,
    5. Slaets L,
    6. Viale G,
    7. Delaloge S, et al.
    70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375: 717–29.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords